Development and application of rodent models for type 2 diabetes

被引:129
作者
Chen, D [1 ]
Wang, MW [1 ]
机构
[1] Chinese Acad Sci, Shanghai Inst Mat Med, Natl Ctr Drug Screening, Shanghai 201203, Peoples R China
关键词
pharmacology; rodents; type; 2; diabetes;
D O I
10.1111/j.1463-1326.2004.00392.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The increasing worldwide incidence of diabetes in adults constitutes a global public health burden. It is predicted that by 2025, India, China and the United States will have the largest number of people with diabetes [1]. According to the 2003 estimates of the International Diabetes Federation, the diabetes mellitus prevalence in the USA is 8.0% and approximately 90-95% of diabetic Americans have type 2 diabetes - about 16 million people. Type 2 diabetes is a complex, heterogeneous, polygenic disease characterized mainly by insulin resistance and pancreatic P-cell dysfunction. Appropriate experimental models are essential tools for understanding the molecular basis, pathogenesis of the vascular and neural lesions, actions of therapeutic agents and genetic or environmental influences that increase the risks of type 2 diabetes. Among the animal models available, those developed in rodents have been studied most thoroughly for reasons such as short generation time, inherited hyperglycaemia and/or obesity in certain strains and economic considerations. In this article, we review the current status of most commonly used rodent diabetic models developed spontaneously, through means of genetic engineering or artificial manipulation. In addition to these models, the Psammomys obesus, rhesus monkeys and many other species are studied intensively and reviewed by Shaffir [2], Bailey and Flatt [3,4] and Hansen [5].
引用
收藏
页码:307 / 317
页数:11
相关论文
共 79 条
[61]   Ocular vascular endothelial growth factor levels in diabetic rats are elevated before observable retinal proliferative changes [J].
Sone, H ;
Kawakami, Y ;
Okuda, Y ;
Sekine, Y ;
Honmura, S ;
Matsuo, K ;
Segawa, T ;
Suzuki, H ;
Yamashita, K .
DIABETOLOGIA, 1997, 40 (06) :726-730
[62]   Prevention of hyperglycemia in the Zucker diabetic fatty rat by treatment with metformin or troglitazone [J].
Sreenan, S ;
Sturis, J ;
Pugh, W ;
Burant, CF ;
Polonsky, KS .
AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM, 1996, 271 (04) :E742-E747
[63]   Glucagon-like peptide-1 stimulates insulin secretion by a Ca2+-independent mechanism in Zucker diabetic fatty rat islets of langerhans [J].
Sreenan, SK ;
Mittal, AA ;
Dralyuk, F ;
Pugh, WL ;
Polonsky, KS ;
Roe, MW .
METABOLISM-CLINICAL AND EXPERIMENTAL, 2000, 49 (12) :1579-1587
[64]   Chronic inhibition of circulating dipeptidyl peptidase IV by FE 999011 delays the occurrence of diabetes in male Zucker diabetic fatty rats [J].
Sudre, B ;
Broqua, P ;
White, RB ;
Ashworth, D ;
Evans, DM ;
Haigh, R ;
Junien, JL ;
Aubert, ML .
DIABETES, 2002, 51 (05) :1461-1469
[65]   An early insulin intervention accelerates pancreatic beta-cell dysfunction in young Goto-Kakizaki rats, a model of naturally occurring noninsulin-dependent diabetes [J].
Suzuki, N ;
Aizawa, T ;
Asanuma, N ;
Sato, Y ;
Komatsu, M ;
Hidaka, H ;
Itoh, N ;
Yamauchi, K ;
Hashizume, K .
ENDOCRINOLOGY, 1997, 138 (03) :1106-1110
[66]   Glucagon-like peptide 1 receptor agonist ZP10A increases insulin mRNA expression and prevents diabetic progression in db/db mice [J].
Thorkildsen, C ;
Neve, S ;
Larsen, BD ;
Meier, E ;
Petersen, JS .
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2003, 307 (02) :490-496
[67]   EVOLUTION OF BETA-CELL DYSFUNCTION IN THE MALE ZUCKER DIABETIC FATTY RAT [J].
TOKUYAMA, Y ;
STURIS, J ;
DEPAOLI, AM ;
TAKEDA, J ;
STOFFEL, M ;
TANG, JP ;
SUN, XH ;
POLONSKY, KS ;
BELL, GI .
DIABETES, 1995, 44 (12) :1447-1457
[68]   Persistent improvement of type 2 diabetes in the Goto-Kakizaki rat model by mass during the prediabetic expansion of the β-cell period with glucagon-like peptide-1 or exendin-4 [J].
Tourrel, C ;
Bailbe, D ;
Lacorne, M ;
Meile, MJ ;
Kergoat, M ;
Portha, B .
DIABETES, 2002, 51 (05) :1443-1452
[69]  
TSUURA Y, 1994, DIABETOLOGIA, V37, P1082, DOI 10.1007/BF00418371
[70]   Diseases of liporegulation: new perspective on obesity and related disorders [J].
Unger, RH ;
Orci, L .
FASEB JOURNAL, 2001, 15 (02) :312-321